stockrowAmylyx Pharmaceuticals, Inc.
AMLX Healthcare Drug Manufacturers Specialty & Generic
Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023.
- Revenue
- −100.6%
- EPS
- +15.2%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow AMLX
Alert me
Amylyx Pharmaceuticals, Inc. (AMLX) EPS (diluted)
Amylyx Pharmaceuticals, Inc.'s EPS (diluted) for fiscal 2025 was −$1.53, compared with −$4.43 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$1.43. Over the past ten years it has ranged from −$13.35 (fiscal 2021) to $0.70 (fiscal 2023); the current reading is higher than 83% of that period. Amylyx Pharmaceuticals, Inc. ranks 59th of 75 Drug Manufacturers Specialty & Generic companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.53 | — |
| FY2024 | −$4.43 | — |
| FY2023 | $0.70 | — |
| FY2022 | −$3.39 | — |
| FY2021 | −$13.35 | — |
| FY2020 | −$6.96 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.39 | — |
| Mar 2026 | −$0.37 | — |
| Dec 2025 | −$0.30 | — |
| Sep 2025 | −$0.37 | — |
| 18 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| SUPN Indivior Pharmaceuticals Inc. compare | $3.58 |
| PBH Prestige Consumer Healthcare Inc. compare | $3.24 |
| LQDA Liquidia Corporation compare | $1.37 |
| HIMS Hims & Hers Health, Inc. compare | −$0.63 |
| AMLX Amylyx Pharmaceuticals, Inc. | −$1.43 |
| TRLV Trulieve Cannabis Corp. compare | −$2.47 |
| PRGO Perrigo Company plc compare | −$12.76 |
| RGC Regencell Bioscience Holdings Limited compare | — |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | — |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on AMLX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement